L20 @ #ACR23 New therapy on the horizon for RA pts that failed MTX? ⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL ➡️ placebo-controlled, phase III trial, 24w 👉at wk 24, PBO pts switched to drug arm for 24 more wks ➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6

Agimeteran a TLR7/8i 30 mg in #cutaneous #lupus which differentiated from placebo. Small single site #RCT. Far more pts improved #CLASI by 50% vs PBO #ACR23 #ACRbest ⁦@RheumNow⁩ ⁦@ACRheum⁩ L15 In larger RCT now! https://t.co/zssjgpydVY

#IA Injection in #knee #OA. TLC599 vs #dexamethasone vs saline #RCT-blinded. Both active #Rx better than #PBO. Some differences in average daily pain between active drugs. Not sure where it may fit in? After IA steroid failure? L18 #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ https://t.co/rLh6ISBpUw

Inflammation in interstitial fibrosis & tubular atrophy (i-IFTA) is assoc w/ GFR loss accdg to this study by Dr SMalvica et al. ✳️In pts w/ mod-to-severe IFTA, the degree of i-IFTA was assoc'd with higher risk of GFR loss #ACR23 ABST2552 @RheumNow https://t.co/7iA0nzbmgM

Bastard et al. 12,071 French PsA. Low incidence serious infections on advanced therapy - 17 per 1,000 person-years. Significantly lower risk ETN (HR 0.70), UST (HR 0.56) vs ADA. Others similar. Abstr#2566 #ACR23 @RheumNow https://t.co/GGDvRxP9ht https://t.co/Ol7G1OG73t

Interesting look into autoantibody profile of rheumatic disease-ILD compared to IPF Identified 7 ab in RD-ILD, emphasizing lack of autoimmunity in IPF Different mechanisms of damage and progression based on ab profile? @RheumNow #ACR23 Abs#2572 https://t.co/5rtXnOe9oJ

#ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis -Anti-NT5c1A assoc with dysphagia -Anti-Ro52/TRIM21: female -Anti-VCP: male -Anti-NT5c1A + clinical markers: high accuracy in separating SIBM vs AIM Need longitudinal data for clusters to be meaningful @RheumNow https://t.co/fu0a074XAZ

Beware of the « HOT stuff 🌶️ bias » In his very didactic catalogue of bias, Timothy McAlindon particularly warns us against the hot stuff, or the tendency to be less rigorous in the scientific approach when a topic is fashionable @RheumNow #ACR23 https://t.co/rS8lItDrGS

#ACR23 Abstr#2580 Could high-intensity resistance training improve outcomes in myositis? RCT showed 16 wks of training was tolerable, improved quality of life & functional capacity, without increasing disease activity/damage @RheumNow https://t.co/O1nP2x9C1L

#ACR23 BEST Abstracts from San Diego – Day 1 From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from 11/12/23. You can spot these on Twitter by looking for the (#ACRbest) hashtag. https://t.co/h4RvFy66z9 https://t.co/LEhAUaw6Cj